Thermo Fisher Scientific Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation decreased by 5099.2% to -$6.60B in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase signals strong cash generation or financing activity, while a decrease may indicate heavy capital investment or debt repayment.
This metric measures the net change in the total liquidity position, including cash, cash equivalents, and restricted ca...
A fundamental cash flow metric reported by all public companies.
other_cash_cash_equivalents_restricted_cash_and_restrict_8b4577| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $132.00M | -$6.60B |
| QoQ Change | — | <-999% |
| YoY Change | — | <-999% |